Prevalence and coexistence of type 2 inflammatory diseases.

Autor: Mora T; Research Institute for Evaluation and Public Policies, Universitat Internacional de Catalunya (UIC), Barcelona, Catalonia, Spain., Sánchez-Collado I; Research Institute for Evaluation and Public Policies, Universitat Internacional de Catalunya (UIC), Barcelona, Catalonia, Spain., Muñoz-Cano R; Allergy Department, Universitat de Barcelona, Hospital Clinic, Barcelona, Catalonia, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain.; RICORS, Instituto de Salud Carlos III, Madrid, Spain., Ribó P; Allergy Department, Universitat de Barcelona, Hospital Clinic, Barcelona, Catalonia, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain.; CIBER of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Palomo-Jiménez PI; Sanofi, Madrid, Spain., Mullol J; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain.; CIBER of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain., Valero A; Allergy Department, Universitat de Barcelona, Hospital Clinic, Barcelona, Catalonia, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain.; CIBER of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Jazyk: angličtina
Zdroj: Clinical and translational allergy [Clin Transl Allergy] 2024 Jun; Vol. 14 (6), pp. e12376.
DOI: 10.1002/clt2.12376
Abstrakt: Background: Type 2 inflammation has been described as a pathophysiological basis common to some diseases, such as atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps, and asthma (CRSwNP).
Objective: The present study used population-based prevalence in Catalonia to analyse the coexistence of type 2 inflammatory diseases in patients primarily diagnosed with the above mentioned conditions.
Results: We found a high degree of coexistence of type 2 inflammatory diseases among these patients, with the prevalence being higher in the severe forms, except for AD. For the severe forms of primary diseases, the proportion of patients with coexisting type 2 inflammatory diseases (severe or non-severe) was 16.2% for AD, 19.8% for asthma, and a striking 62.4% for CRSwNP. This patient population has the highest proportion of coexisting type 2 inflammatory diseases, both severe (48.9%) and non-severe (13.5%).
Conclusion: Our findings have significant implications for the management of patients with AD, asthma, and CRSwNP.
(© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje